Table 3.
Factors associated with death among HIV-infected cervical cancer patients (Delta CD4, n=139)
| Category | Crude HR (95% CI) | Adjusted HR (95% CI) | |
|---|---|---|---|
| Delta CD4 (cells/mm3) (Categorical) | < 100 | 1.00 | 1.00 |
| 100–249 | 0.59 (0.31–1.15) | 0.45 (0.21–0.95) | |
| ≥ 250 | 0.41 (0.20–0.82) | 0.45 (0.20–1.02) | |
| Age (years) | 1.00 (0.96–1.03) | 1.02 (0.98–1.06) | |
| Hemoglobin at baseline (g/dl) | 1st quartile (4.1–9.0) | 1.00 | 1.00 |
| 2nd quartile (9.1–10.4) | 1.43 (0.66–3.10) | 1.72 (0.71–4.19) | |
| 3rd quartile (10.5–12.1) | 0.72 (0.28–1.82) | 0.60 (0.21–1.76) | |
| 4th quartile (12.2–15.3) | 0.45 (0.18–1.15) | 0.46 (0.16–1.30) | |
| Missing | 1.34 (0.46–3.94) | 1.29 (0.39–4.27) | |
| Stage | Stage I | 1.00 | 1.00 |
| Stage II | 1.89 (0.66–5.47) | 1.12 (0.34–3.66) | |
| Stage III | 1.73 (0.59–5.12) | 0.59 (0.18–2.00) | |
| Stage IV | 2.21 (0.49–9.92) | 0.62 (0.11–3.64) | |
| RT dose (EQD2) | 1st quartile (9.3–63.9) | 1.00 | 1.00 |
| 2nd quartile (64.0–77.9) | 0.52 (0.25–1.08) | 0.70 (0.29–1.71) | |
| 3rd quartile (78.0–80.5) | 0.38 (0.17–0.82) | 0.28 (0.12–0.70) | |
| 4th quartile (80.6–89.5) | 0.38 (0.17–0.85) | 0.41 (0.15–1.09) | |
| Number of chemo cycles | None | 1.00 | 1.00 |
| 1–5 | 0.32 (0.18–0.59) | 0.43 (0.21–0.88) | |
| Missing | 0.62 (0.23–1.66) | 1.46 (0.46–4.61) | |
| Performance status (KPS*) | ≤ 80 | 1.00 | 1.00 |
| > 80 | 0.82 (0.44–1.55) | 0.69 (0.34–1.41) | |
| Missing | 0.31 (0.09–1.07) | 0.16 (0.04–0.64) | |
| Nadir CD4 cells/mm3 (continuous by 100) | 1.07 (0.92–1.25) | 1.03 (0.86–1.25) |
*
KPS: Karnofsky Performance Status